+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4802096
  • Report
  • Region: Global
  • 100 pages
  • Infinium Global Research
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Adamis Laboratories, Inc.
  • AstraZeneca plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
The report on the global chronic obstructive pulmonary disease therapeutics market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global chronic obstructive pulmonary disease therapeutics market to grow with a healthy CAGR over the forecast period from 2019-2025. The study on chronic obstructive pulmonary disease therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on chronic obstructive pulmonary disease therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global chronic obstructive pulmonary disease therapeutics market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global chronic obstructive pulmonary disease therapeutics market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings
1) Drivers
  • Persistent rise in the number of COPD cases globally
  • Increasing the number of tobacco smokers and prolong exposure to polluted air environments
2) Restraints
  • Lack of knowledge and awareness regarding COPD indication and symptoms
3) Opportunities
  • Strong pipeline drugs and rising government initiatives
Research Methodology

A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with the author
2. Internal and External subject matter experts
3. Professionals and participants from the industry
The primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global chronic obstructive pulmonary disease therapeutics market is segmented on the basis of drug class, and distribution channel.

The Global Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class
  • Bronchodilators
  • Combination
  • Phosphodiesterase Type 4 Inhibitors
  • Mucokinetics
  • Corticosteroids
  • Other Drug Class
The Global Chronic Obstructive Pulmonary Disease Therapeutics Market by Distribution Channel
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Company Profiles

The companies covered in the report include
  • Pfizer Inc.
  • Adamis Laboratories, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the chronic obstructive pulmonary disease therapeutics market.
2. Complete coverage of all the segments in the chronic obstructive pulmonary disease therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global chronic obstructive pulmonary disease therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adamis Laboratories, Inc.
  • AstraZeneca plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Chronic Obstructive Pulmonary Disease Therapeutics Market Highlights
2.2. Chronic Obstructive Pulmonary Disease Therapeutics Market Projection
2.3. Chronic Obstructive Pulmonary Disease Therapeutics Market Regional Highlights

3. Global Chronic Obstructive Pulmonary Disease Therapeutics Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Drug Class
3.4.2. Growth Matrix Analysis by Distribution Channel
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Chronic Obstructive Pulmonary Disease Therapeutics Market

4. Chronic Obstructive Pulmonary Disease Therapeutics Market Macro Indicator Analysis

5. Global Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class
5.1. Bronchodilators
5.2. Combination
5.3. Phosphodiesterase Type 4 Inhibitors
5.4. Mucokinetics
5.5. Corticosteroids
5.6. Other Drug Class

6. Global Chronic Obstructive Pulmonary Disease Therapeutics Market by Distribution Channel
6.1. Online Pharmacies
6.2. Hospital Pharmacies
6.3. Retail Pharmacies

7. Global Chronic Obstructive Pulmonary Disease Therapeutics Market by Region 2019-2025
7.1. North America
7.1.1. North America Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class
7.1.2. North America Chronic Obstructive Pulmonary Disease Therapeutics Market by Distribution Channel
7.1.3. North America Chronic Obstructive Pulmonary Disease Therapeutics Market by Country
7.2. Europe
7.2.1. Europe Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class
7.2.2. Europe Chronic Obstructive Pulmonary Disease Therapeutics Market by Distribution Channel
7.2.3. Europe Chronic Obstructive Pulmonary Disease Therapeutics Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class
7.3.2. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market by Distribution Channel
7.3.3. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market by Country
7.4. RoW
7.4.1. RoW Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class
7.4.2. RoW Chronic Obstructive Pulmonary Disease Therapeutics Market by Distribution Channel
7.4.3. RoW Chronic Obstructive Pulmonary Disease Therapeutics Market by Sub-region

8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market
8.2. Companies Profiles
8.2.1. Pfizer Inc.
8.2.2. Adamis Laboratories, Inc.
8.2.3. AstraZeneca plc
8.2.4. Boehringer Ingelheim Pharmaceuticals, Inc.
8.2.5. Novartis AG
8.2.6. Sunovion Pharmaceuticals, Inc.

9. Appendix
9.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer Inc.
  • Adamis Laboratories, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll